Region — US. Neutral scientific reference — not offered for sale here.
Research reference — not for sale
Peptide⚠ WADA-banned
also called — GHRP-2 · Growth Hormone Releasing Peptide-2 · INN pralmorelin · developer codes KP-102 / GPA-748 · Japanese product GHRP Kaken 100 · sequence D-Ala-D-2-Nal-Ala-Trp-D-Phe-Lys-NH₂ (MW ~818 Da). INCI: none
GH secretagogue / ghrelin agonist(approved: GH-deficiency diagnostic)body composition (off-label)
Reference entry — not sold here. Notable as the only GHRP with a regulatory approval anywhere — but that approval is a diagnostic one (Japan), not a therapy. No dosing published here.
In brief
GHRP-2 (pralmorelin) is a ghrelin-receptor agonist and the only GHRP with a regulatory approval — in Japan, as a diagnostic agent for GH deficiency. It reliably raises GH (the most potent GHRP per microgram) with intermediate selectivity — moderate cortisol/prolactin and appetite effects (more than Ipamorelin, less than GHRP-6). But the approval is diagnostic-only; the popular anti-aging / body-composition use is untested in humans. It is banned in sport.
Legal standing, by region
European Union
Not approved
not approved.
United States · your region
Not FDA-approved (gray-market)
not FDA-approved; has not been through the FDA drug-approval process (503A Category-2 / gray-market for off-label use).
⚠ WADA-prohibited in sportSport: WADA-prohibited at all times — Section S2.2 (GH secretagogues).
Evidence, by outcome
An honest grade per outcome — drawn from the evidence, not any catalogue. Hype and undemonstrated marketing claims grade low.
OutcomeEvidence base · effectGrade
GH release (diagnostic)
Real but narrow; diagnostic-focused; single company
Approved diagnostic (Japan) + ~4 human trials (~170) · Consistent dose-dependent GH elevation (peak 15–30 min)
BGH-deficiency diagnostic testing (approved, Japan)
Approved diagnostic use only
Kaken trials; accuracy competitive with the insulin-tolerance test · Reliable provocative test
BAnti-aging / body composition (the popular use)
Untested for these goals
None in humans · Not demonstrated
FSafety
Raises cortisol/prolactin (moderate) + appetite; long-term unknown; WADA-banned
Diagnostic use + PK data · Characterised (short-term)
—Identity a synthetic hexapeptide (6 amino acids, < 40 aa → peptide), a ghrelin-receptor (GHS-R1a) agonist that stimulates GH release from the anterior pituitary. It is the most potent GHRP per microgram for GH release, with intermediate selectivity — sitting between the non-selective GHRP-6 (#24) and the highly selective Ipamorelin (#17). ## Development & history - Developed in the 1990s as a more potent evolution of GHRP-6 (Bowers' original GHRP).
- Approved in Japan (PMDA) as pralmorelin (GHRP Kaken 100) — a diagnostic agent for assessing GH deficiency (the GHRP-2 stimulation test), marketed by Kaken Pharmaceutical since ~2004. This makes GHRP-2 the only GHRP to achieve regulatory approval by any national authority.
- Its human evidence base is narrow but real: ~4 published trials (~170 participants), all from Kaken, focused on diagnostic accuracy. ## Mechanism (as proposed) a GHS-R1a (ghrelin-receptor) agonist on pituitary somatotrophs → GH release; it also suppresses somatostatin (a dual stimulatory mechanism) and is synergistic with GHRH (co-administration amplifies GH several-fold). Notably, GH release plateaus above ~ while cortisol and prolactin keep rising dose-dependently — the basis of its intermediate-selectivity profile.
Sources — 2 cited
01Bowers CY, et al. — foundational GHRP characterisation (the class GHRP-2 descends from).
02Kaken Pharmaceutical pralmorelin (GHRP Kaken) diagnostic trials; PMDA approval (Japan).
Review status
Not yet reviewed
A credentialed reviewer (PharmD / PhD / MD) will be named before this entry is finalised. Until then, treat it as a working draft. Last updated July 2026.
Grades reflect the published evidence, not our interest. No dosing, reconstitution, or administration is published for research compounds — that restraint is deliberate.
VallydiaA neutral reference and a lawful-lane shop. Registered in Spain. Information for those who seek it — never promotion.
Region — United States
This site provides neutral scientific reference and sells only products lawful in your region. Nothing here is medical advice, a recommendation, or an offer to supply unapproved medicines. No dosing or administration is published for research compounds. Cosmetic peptides per Regulation (EC) 1223/2009. Unapproved injectable peptides are neither sold nor advertised in the EU (Directive 2001/83/EC, Title VIII). © 2026 Vallydia SL — Registered in Spain.